Kiang Liu

Kiang Liu

Auto-generated profile, based on publicly available information

Kiang Liu

Department of Preventive Medicine Northwestern University Chicago IL

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
KLKiang Liu
Kiang Liu
MDMartha L. Daviglus
Martha L. Daviglus
CLCatherine M. Loria
Catherine M. Loria
LCLaura A. Colangelo
Laura A. Colangelo
BSBonnie Spring
Bonnie Spring
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Background—: A low cardiovascular disease risk profile (untreated cholesterol <200 mg/dL, untreated blood pressure <120/<80 mm Hg, never smoking, and no history of diabetes mellitus or myocardial infarction) in middle age is associated with markedly better health outcomes in older age, but few middle-aged adults have this low risk profile. We examined whether adopting a healthy lifestyle throughout young adulthood is associated with the presence of the low cardiovascular disease risk profile in middle age. Methods and Results—: The Coronary Artery Risk Development in (Young) Adults (CARDIA) study sample consisted of 3154 black and white participants 18 to 30 years of age at year 0 (1985–1986) who attended the year 0, 7, and 20 examinations. Healthy lifestyle factors defined at years 0, 7, and 20 included average body mass index <25 kg/m 2 , no or moderate alcohol intake, higher healthy diet score, higher physical activity score, and never smoking. Mean age (25 years) and percentage of women (56%) were comparable across groups defined by number of healthy lifestyle factors. The age-, sex-, and race-adjusted prevalences of low cardiovascular disease risk profile at year 20 were 3.0%, 14.6%, 29.5%, 39.2%, and 60.7% for people with 0 or 1, 2, 3, 4, and 5 healthy lifestyle factors, respectively ( P for trend <0.0001). Similar graded relationships were observed for each sex-race group (all P for trend <0.0001). Conclusions—: Maintaining a healthy lifestyle throughout young adulthood is strongly associated with a low cardiovascular disease risk profile in middle age. Public health and individual efforts are needed to improve the adoption and maintenance of healthy lifestyles in young adults.

25 August 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
BJBrian Joyce
Brian Joyce
TGTao Gao
Tao Gao
YZYinan Zheng
Yinan Zheng
JMJiantao Ma
Jiantao Ma
SHShih-Jen Hwang
Shih-Jen Hwang
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Rationale: Epigenetic aging is a novel measure of biological age, reflecting exposures and disease risks independent of chronological age. It may serve as a useful biomarker of cardiovascular health (CVH) or cardiovascular disease risk for early detection or prevention. Objective: To examine associations between GrimAge acceleration (GrimAA), a measure of epigenetic aging calculated from the residuals of GrimAge regressed on chronological age, and 2 repeated CVH measures: a full score for the AHA Life’s Simple 7 (diet, smoking, physical activity, body mass index, blood pressure, total cholesterol, and glucose) and a clinical CVH score (body mass index, blood pressure, cholesterol, and glucose). Methods and Results: We used Illumina array DNA methylation data from 2 prospective cohort studies, the CARDIA study (Coronary Artery Risk Development in Young Adults) and FHS (Framingham Heart Study), to calculate GrimAA and model associations with CVH. CARDIA randomly selected 1118 participants for assays at Y15 (2000–2001; mean age, 40 years) and Y20 (2005–2006); in FHS, 2106 Offspring participants had DNA methylation measured at exam 8 (2005–2008; mean age, 66 years). We examined multiple cross-sectional and longitudinal models of GrimAA and each CVH score measured at CARDIA Y0 to Y20 and FHS exams 7 to 8. In CARDIA, clinical CVH score from Y0 to Y20 was associated with Y15 and Y20 GrimAA (β range, −0.41 to −0.21 years per 1-point increase in CVH; P range, <0.01–0.01), as was full score (β range, −0.65 to −0.67 years; P <0.01 for all). These findings were validated in FHS (clinical score β range, −0.51 to −0.54 years; full score β range, −0.76 to −0.83 years; P <0.01 for all). Conclusions: Our data demonstrate that faster GrimAA is associated with the loss of CVH from young age. Epigenetic age may be a useful biomarker of cardiovascular disease risk and provides biological insight into the role of epigenetic mechanisms linking age-related CVH loss and cardiovascular disease.

10 April 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PWPhilipp Wild
Philipp Wild
JFJanine F. Felix
Janine F. Felix
ASArne Schillert
Arne Schillert
ATAlexander Teumer
Alexander Teumer
MCMing-Huei Chen
Ming-Huei Chen
MDMarcus Dörr
Marcus Dörr
BACKGROUND. Understanding the genetic architecture of cardiac structure and function may help to prevent and treat heart disease. This investigation sought to identify common genetic variations associated with inter-individual variability in cardiac structure and function. METHODS. A GWAS meta-analysis of echocardiographic traits was performed, including 46,533 individuals from 30 studies (EchoGen consortium). The analysis included 16 traits of left ventricular (LV) structure, and systolic and diastolic function. RESULTS. The discovery analysis included 21 cohorts for structural and systolic function traits (n = 32,212) and 17 cohorts for diastolic function traits (n = 21,852). Replication was performed in 5 cohorts (n = 14,321) and 6 cohorts (n = 16,308), respectively. Besides 5 previously reported loci, the combined meta-analysis identified 10 additional genome-wide significant SNPs: rs12541595 near MTSS1 and rs10774625 in ATXN2 for LV end-diastolic internal dimension; rs806322 near KCNRG, rs4765663 in CACNA1C, rs6702619 near PALMD, rs7127129 in TMEM16A, rs11207426 near FGGY, rs17608766 in GOSR2, and rs17696696 in CFDP1 for aortic root diameter; and rs12440869 in IQCH for Doppler transmitral A-wave peak velocity. Findings were in part validated in other cohorts and in GWAS of related disease traits. The genetic loci showed associations with putative signaling pathways, and with gene expression in whole blood, monocytes, and myocardial tissue. CONCLUSION. The additional genetic loci identified in this large meta-analysis of cardiac structure and function provide insights into the underlying genetic architecture of cardiac structure and warrant follow-up in future functional studies. FUNDING. For detailed information per study, see Acknowledgments.

16 September 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KLKiang Liu
Kiang Liu
LCLaura A. Colangelo
Laura A. Colangelo
MDMartha L. Daviglus
Martha L. Daviglus
DGDavid C. Goff
David C. Goff
MPMark Pletcher
Mark Pletcher
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Background: It is unclear whether antihypertensive treatment can restore cardiovascular disease risk to the risk level of persons with ideal blood pressure ( BP ) levels. Methods and Results: Data from the Multi‐Ethnic Study of Atherosclerosis ( MESA ) and the Coronary Artery Risk Development in Young Adults ( CARDIA ) study were analyzed. Outcomes were compared among participants without or with antihypertensive treatment at 3 BP levels: <120/<80 mm Hg, systolic BP 120 to 139 mm Hg or diastolic BP 80 to 89 mm Hg (120 to 129/≤80 mm Hg for participants with diabetes), and systolic BP ≥140 or diastolic BP ≥90 mm Hg (systolic BP ≥130 or diastolic BP ≥80 mm Hg for participants with diabetes). Among MESA participants aged ≥50 years at baseline, those with BP <120/<80 mm Hg on treatment had higher left ventricular mass index, prevalence of estimated glomerular filtration rate 100, and twice the incident cardiovascular disease rate over 9.5 years of follow‐up than those with BP <120/<80 mm Hg without treatment. In CARDIA at year 25, persons with BP <120/<80 mm Hg with treatment had much longer exposure to higher BP and higher risk of end‐organ damage and subclinical atherosclerosis than those with BP <120/3000 mm Hg–years in 25 years), the increase in left ventricular mass index accelerated. Conclusions: The data suggest that based on the current approach, antihypertensive treatment cannot restore cardiovascular disease risk to ideal levels. Emphasis should be placed on primordial prevention of BP increases to further reduce cardiovascular disease morbidity and mortality.

1 April 2002
Verified
Journal Article
Closed access
LCLaura A Colangelo
Laura A Colangelo
SGSusan M Gapstur
Susan M Gapstur
PGPeter H Gann
Peter H Gann
ADAlan R Dyer
Alan R Dyer
KLKiang Liu
Kiang Liu

1 August 2009 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
CHChiang-Ching Huang
Chiang-Ching Huang
MFMyriam Fornage
Myriam Fornage
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
GWGina S. Wei
Gina S. Wei
EBEric Boerwinkle
Eric Boerwinkle
KLKiang Liu
Kiang Liu
Background— Mutations of PCSK9 are associated cross-sectionally with plasma low-density lipoprotein cholesterol (LDL-C) levels, but little is known about their longitudinal association with LDL-C levels from young adulthood to middle age. Methods and Results— We investigated the associations of 6 PCSK9 variants with LDL-C over 20 years in 1750 blacks and 1828 whites from the Coronary Artery Risk Development In Young Adults study. Generalized estimating equations were used to assess longitudinal differences in LDL-C levels between genotype categories. For blacks, LDL-C levels at age 18 were significantly lower ( P <0.001) among those with 3 genetic variants (L253F, C679X, and Y142X; 81.5 mg/dL) and A443T (95.5 mg/dL) compared with noncarriers (109.6 mg/dL). The difference in LDL-C levels from noncarriers tended to widen for those with the 3 variants only, by 0.24 mg/dL per year of age ( P =0.14). For whites with the R46L variant, compared with noncarriers, LDL-C levels at age 18 were significantly lower (84.4 mg/dL versus 100.9 mg/dL; P <0.001), and the increase in LDL-C with age was similar to noncarriers. The 3 genetic variants and the A443T variant in black men were associated with lower carotid intima-media thickness and lower prevalence of coronary calcification measured at ages 38 to 50. Conclusions— Our results suggest that participants with several genetic variants of PCSK9 have persistently lower serum LDL-C levels than noncarriers from ages 18 to 50. Such long-term reduction in LDL-C levels is associated with reduced subclinical atherosclerosis burden in black men.